Following the onset of nonarteritic anterior ischemic optic neuropathy, regular stroke workup may be necessary.

Use of once-weekly semaglutide more than doubles the risk for nonarteritic anterior ischemic optic neuropathy (NAION) in individuals with type 2 diabetes.

Semaglutide is associated with nonarteritic anterior ischemic optic neuropathy (NAION) among patients with type 2 diabetes (T2D) and those with overweight/obesity.

Get Instant Summarized Text (Gist) Once-weekly semaglutide use in individuals with type 2 diabetes more than doubles the risk of developing nonarteritic anterior ischemic optic neuropathy (NAION ...

Semaglutide exposure was significantly associated with a higher incidence rate and independently predicted a higher risk for upcoming nonarteritic anterior ischemic optic neuropathy. HealthDay ...

TUESDAY, Jan. 14, 2025 (HealthDay News) -- Use of once-weekly semaglutide more than doubles the risk for nonarteritic anterior ischemic optic neuropathy (NAION) in individuals with type 2 diabetes ...

Findings seen for patients with type 2 diabetes during a 5-year period. (HealthDay News) — Use of once-weekly semaglutide more than doubles the risk for nonarteritic anterior ischemic optic ...

The safety committee of the European Medicines Agency (EMA) will again study the medication, semaglutide, out of concerns ...

Spread This NewsCity Press Globally, people wanting to lose weight are turning to Ozempic, the so-called miracle drug ...